Syracuse,
NY, USA -- Monaghan Medical Corporation (MMC) today announced
that a new study presented to the American College of Chest
Physicians (CHEST) shows MMC's Aerobika®
device is effective in reducing drug use for treatment of Chronic
Obstructive Pulmonary Disease (COPD).
COPD
is a major source of morbidity and mortality in the United States.(i)
The Center for Disease Control estimates that COPD medical visits,
hospital admissions and lost time costs 36 billion dollars
annually.(ii) The recommended course of treatment for acute
COPD exacerbations includes antibiotics and oral corticosteroids
(OCS).(iii)
The
study results revealed today at the CHEST Annual Meeting in Los
Angeles, show that those study patients who used the Aerobika®
device experienced a significant reduction (57% and 89% reduction,
respectively) in the use of antibiotics and OCS in the hospital
setting compared to those study patients who did not use the
Aerobika® device in addition to the regular COPD
medication treatment. These findings are part of a larger 6-month
retrospective study that demonstrated a 28% reduction in
exacerbations in as little as 30 days of treatment, when used as an
add-on to usual COPD medications.
COPD
exacerbations can be caused by viral or bacterial infections, in fact
pulmonary infections are associated with 50% of COPD hospital
admissions(iv) and higher mortality rates.(v)
Overproduction of mucous leads to increased rates of infection and
inflammation contributing significantly to morbidity and mortality in
COPD.(vi)
This
study showed for patients in the Aerobika® device
cohort, antibiotics were used 57% less and oral corticosteroids were
used 89% less than for the cohort without the Aerobika®
device within 6 months' post-exacerbation. The decreased need for
short-term drug therapies including antibiotics and OCS, may have
reflected better disease control with those patients who used the
non-drug device. Additionally, patients in the Aerobika®
device cohort exhibited significantly lower costs throughout the
study period with an average reduction of $6,347 USD and $9,936 USD
per patient at 30 days and 6 months respectively for all in-patient
and out-patient hospital costs.
"One
of our major goals in developing the Aerobika® device
was to safely improve patient outcomes," said Dominic Coppolo,
MBA, RRT, FAARC, Vice President Clinical Strategy and Development at
Monaghan Medical. "These real-world findings are encouraging as
we continue to conduct additional studies to further demonstrate the
impact of our device in this high risk patient population."
The
projected cost of COPD in the U.S. by 2020 has been calculated at $49
billion.(vii) Since COPD exacerbations account for the
greatest proportion of burden on healthcare systems,(viii) and
readmissions are unwanted and expensive, the simplest way to reduce
hospital admissions for COPD is to reduce exacerbations.(ix)
About
the Aerobika®
device study: A 6-month retrospective cohort study of the US
hospital Charge Detail Master (CDM) claims database, conducted
between September 2013 and August 2015. This real-word study involved
810 COPD patients with a diagnosis of chronic bronchitis, 405
receiving treatment with the Aerobika® device and 405
propensity score matched controls. The primary outcome was the
proportion of patients with moderate-to-severe and severe
exacerbations at 30 days. Secondary measures included resource
utilization and costs associated with exacerbations.
About
The Aerobika®
Device
The
Aerobika® device is hand-held, easy-to-use, and
drug-free. When the patient exhales through the device, intermittent
resistance creates positive pressure and oscillations simultaneously,
which expands the airways, helps expel the mucus to the upper airways
where it can be coughed out and may also aid in improved drug
deposition. The Aerobika® device is available in
Canada, Mexico, and select European countries including the UK and
Germany through Trudell Medical International and in the US via
Monaghan Medical Corporation.
(http://www.trudellmed.com/products/aerobika)
About
Monaghan Medical Corporation (MMC, USA)
MMC
offers leading aerosol drug delivery devices and respiratory
management products including AeroEclipse® II BAN,
AeroChamber Plus® aVHC and the Aerobika®
device exclusively in the United States. MMC's strength lies in
product development around core capabilities in mechanical design
complimented by collaboration with a state-of-the-art aerosol
research laboratory. MMC focuses on developing cost-efficient,
outcome-based solutions for its customers.
(http://www.monaghanmed.com)
For
clinical inquiries, please contact:
Dominic
P. Coppolo, MBA, RRT, FAARC
Vice
President of Clinical Strategy and Development
Monaghan
Medical Corporation
1-800-343-9071
COPD
Facts in USA(x)
• More
than 15 million people report being diagnosed with COPD but millions
more may not have been diagnosed
• COPD
accounts for 10.3 million medical visits and 1.5 million hospital
admissions
• 23
percent of hospitalized patients are re-hospitalized within 30 days
• For
COPD exacerbations, Medicare healthcare expenditures for
re-hospitalization are the third highest
• The
total cost of COPD hospitalizations is estimated at $36 billion per
year
i
Ford ES, et al. Chest 2013;144(1):284-305.
ii
Ford ES, et al. Chest. 2015 Jan;147(1):31-45.
iii
Global Initiative for Chronic Obstructive Lung Disease. Global
strategy for the diagnosis, management, and prevention of chronic
obstructive pulmonary disease. 2015.
iv
Tesfaigzi Y et al. Clinical and Applied Immunology Reviews
2006;6(1):21-36
v
Burgel PR, Martin C. European Respiratory Review 2010;19(116):94-96.
vi
Hogg JC et al. The Nature of Small-Airway Obstruction in Chronic
Obstructive Pulmonary Disease The New England Journal of Medicine
2004;350(26):2645-2653
vii
Ford ES, et al. Chest. 2015 Jan;147(1):31-45.
viii
Khakban A, et al. Am J Respir Crit Care Med. 2016
ix
Mittmann et al. Respir
Med. 2008 Mar;102(3):413-21.
x
Ford ES, et al, Chest. 2015 Jan;147(1):31-45.
